DK3932909T3 - Benzoindazolonforbindelse og mellemprodukt heraf - Google Patents

Benzoindazolonforbindelse og mellemprodukt heraf Download PDF

Info

Publication number
DK3932909T3
DK3932909T3 DK20762099.8T DK20762099T DK3932909T3 DK 3932909 T3 DK3932909 T3 DK 3932909T3 DK 20762099 T DK20762099 T DK 20762099T DK 3932909 T3 DK3932909 T3 DK 3932909T3
Authority
DK
Denmark
Prior art keywords
benzoindazolone
compound
benzoindazolone compound
Prior art date
Application number
DK20762099.8T
Other languages
English (en)
Inventor
Whee Seong Lee
Eun Ju Lee
In Seok Ko
Original Assignee
Lmito Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lmito Therapeutics Inc filed Critical Lmito Therapeutics Inc
Application granted granted Critical
Publication of DK3932909T3 publication Critical patent/DK3932909T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK20762099.8T 2019-02-28 2020-02-20 Benzoindazolonforbindelse og mellemprodukt heraf DK3932909T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190023942A KR102201768B1 (ko) 2019-02-28 2019-02-28 벤조인다졸론 화합물 및 그 용도
PCT/KR2020/002459 WO2020175851A1 (ko) 2019-02-28 2020-02-20 벤조인다졸론 화합물 및 그 제조 중간체

Publications (1)

Publication Number Publication Date
DK3932909T3 true DK3932909T3 (da) 2025-05-26

Family

ID=72239783

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20762099.8T DK3932909T3 (da) 2019-02-28 2020-02-20 Benzoindazolonforbindelse og mellemprodukt heraf

Country Status (11)

Country Link
US (1) US12187683B2 (da)
EP (1) EP3932909B1 (da)
JP (1) JP7359463B2 (da)
KR (1) KR102201768B1 (da)
CN (1) CN113454068B (da)
AU (1) AU2020229601B2 (da)
BR (1) BR112021016912A2 (da)
CA (1) CA3129943C (da)
DK (1) DK3932909T3 (da)
ES (1) ES3021733T3 (da)
WO (1) WO2020175851A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102506406B1 (ko) * 2021-04-19 2023-03-07 주식회사 삼양홀딩스 케토-엔올 변환체 약물을 함유하는 생체 시료의 전처리 방법 및 이에 의하여 전처리된 시료, 및 이 전처리 시료에 대한 정량 분석 방법
KR102678127B1 (ko) * 2021-07-22 2024-06-25 경희대학교 산학협력단 신규한 퀴논 유도체
CN121866049A (zh) 2023-08-21 2026-04-14 法明知识产权股份有限公司 用于在治疗红细胞酶病中使用的醌
CN117247360A (zh) * 2023-09-18 2023-12-19 成都伊诺达博医药科技有限公司 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295626A1 (en) * 1997-07-09 1999-01-21 Peter Cage Novel compounds
KR20080099174A (ko) * 2007-05-07 2008-11-12 주식회사 머젠스 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
CA2935317C (en) * 2013-12-30 2022-11-22 Kt&G Life Sciences Corporation 1,2-naphthoquinone based derivative and method of preparing the same
KR102005068B1 (ko) * 2015-03-27 2019-07-30 주식회사 휴엔 1,2 나프토퀴논 유도체 및 이의 제조방법

Also Published As

Publication number Publication date
US20220144780A1 (en) 2022-05-12
CA3129943A1 (en) 2020-09-03
AU2020229601A1 (en) 2021-09-16
EP3932909A1 (en) 2022-01-05
ES3021733T3 (en) 2025-05-27
EP3932909A4 (en) 2022-12-14
AU2020229601B2 (en) 2022-09-15
US12187683B2 (en) 2025-01-07
WO2020175851A1 (ko) 2020-09-03
BR112021016912A2 (pt) 2021-11-03
KR20200105165A (ko) 2020-09-07
CN113454068B (zh) 2024-08-02
KR102201768B1 (ko) 2021-01-12
JP2022522701A (ja) 2022-04-20
EP3932909B1 (en) 2025-04-02
JP7359463B2 (ja) 2023-10-11
CN113454068A (zh) 2021-09-28
CA3129943C (en) 2024-10-15

Similar Documents

Publication Publication Date Title
DK3946464T3 (da) Forbindelser og konjugater deraf
DK3932919T3 (da) Jak-inhibitorforbindelse og anvendelse deraf
CA189122S (fr) Bracelet
IL285461A (en) Processes and compounds
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK4196479T3 (da) Substituerede pyridotriazinforbindelser og anvendelser deraf
DK4034535T3 (da) Aza-quinolinforbindelser og anvendelser deraf
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf
IL285118A (en) Compounds and uses thereof
DK3932909T3 (da) Benzoindazolonforbindelse og mellemprodukt heraf
DK3919498T6 (da) Pyrrolopyrimidinderivat og anvendelse deraf
EP3957391C0 (en) AGITATOR
EP3939661A4 (en) Patch
DK3953348T3 (da) Forbindelser, sammensætninger og fremgangsmåder
EP3965638C0 (en) VAGINAL SPECULUM
DK3738452T3 (da) Fordamper
EP4063289C0 (en) CROWN CAPSULE
DK3833657T3 (da) Aminothiolester-forbindelser og anvendelser deraf
IT201900025840A1 (it) Composti isotiocianati e isoselencianati
EP4011930A4 (en) PREPREG
DE202019004111U8 (de) Weichenstellvorichtung
EP4051872C0 (en) PRE-BOLTING
CA190864S (fr) Bracelet
EP4011348A4 (en) SHOE INSOLE
TH191175S (th) ต่างหู